OA10918A - Novel 2,3 disubstituted-4(3H)-quinazolinones - Google Patents

Novel 2,3 disubstituted-4(3H)-quinazolinones Download PDF

Info

Publication number: OA10918A
Authority: OA; OAPI
Prior art keywords: alkyl; ajkyl; hydrogen; chloro; fluoro
Prior art date: 1996-05-15

Application number

OA9800216A

Other languages

English (en)

Inventor

Mark Leonard Elliott

Willard Mckowan Welch Jr

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-05-15

Filing date

1998-11-06

Publication date

2001-10-25

1998-11-06 Application filed by Pfizer filed Critical Pfizer

2001-10-25 Publication of OA10918A publication Critical patent/OA10918A/en

Links

-1 2,3 disubstituted-4(3H)-quinazolinones Chemical class 0.000 title claims abstract description 37
238000000034 method Methods 0.000 claims abstract description 34
150000003839 salts Chemical class 0.000 claims abstract description 20
208000014674 injury Diseases 0.000 claims abstract description 13
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
150000001875 compounds Chemical class 0.000 claims description 102
229910052739 hydrogen Inorganic materials 0.000 claims description 89
239000001257 hydrogen Substances 0.000 claims description 74
229910052799 carbon Inorganic materials 0.000 claims description 52
229910052684 Cerium Inorganic materials 0.000 claims description 51
229920002554 vinyl polymer Polymers 0.000 claims description 48
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 44
125000004093 cyano group Chemical group *C#N 0.000 claims description 42
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 39
125000000217 alkyl group Chemical group 0.000 claims description 39
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 32
125000005843 halogen group Chemical group 0.000 claims description 31
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 25
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 24
229910052757 nitrogen Inorganic materials 0.000 claims description 23
125000001309 chloro group Chemical group Cl* 0.000 claims description 22
229940079593 drug Drugs 0.000 claims description 20
239000003814 drug Substances 0.000 claims description 20
239000000203 mixture Substances 0.000 claims description 20
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
206010010904 Convulsion Diseases 0.000 claims description 17
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 17
125000001072 heteroaryl group Chemical group 0.000 claims description 16
206010021143 Hypoxia Diseases 0.000 claims description 14
208000002193 Pain Diseases 0.000 claims description 14
229940127240 opiate Drugs 0.000 claims description 14
238000001356 surgical procedure Methods 0.000 claims description 14
230000007954 hypoxia Effects 0.000 claims description 12
102000003678 AMPA Receptors Human genes 0.000 claims description 11
108090000078 AMPA Receptors Proteins 0.000 claims description 11
125000003545 alkoxy group Chemical group 0.000 claims description 11
206010002027 Amyotrophy Diseases 0.000 claims description 10
208000019901 Anxiety disease Diseases 0.000 claims description 10
206010048962 Brain oedema Diseases 0.000 claims description 10
206010019196 Head injury Diseases 0.000 claims description 10
208000010496 Heart Arrest Diseases 0.000 claims description 10
208000019695 Migraine disease Diseases 0.000 claims description 10
208000028017 Psychotic disease Diseases 0.000 claims description 10
208000017442 Retinal disease Diseases 0.000 claims description 10
206010038923 Retinopathy Diseases 0.000 claims description 10
208000005392 Spasm Diseases 0.000 claims description 10
206010047700 Vomiting Diseases 0.000 claims description 10
230000036506 anxiety Effects 0.000 claims description 10
208000006752 brain edema Diseases 0.000 claims description 10
230000036461 convulsion Effects 0.000 claims description 10
230000003961 neuronal insult Effects 0.000 claims description 10
230000008733 trauma Effects 0.000 claims description 10
208000000094 Chronic Pain Diseases 0.000 claims description 9
208000023105 Huntington disease Diseases 0.000 claims description 9
206010027603 Migraine headaches Diseases 0.000 claims description 9
208000034189 Sclerosis Diseases 0.000 claims description 9
229910052791 calcium Inorganic materials 0.000 claims description 9
230000000747 cardiac effect Effects 0.000 claims description 9
230000006378 damage Effects 0.000 claims description 9
125000001153 fluoro group Chemical group F* 0.000 claims description 9
208000028867 ischemia Diseases 0.000 claims description 9
210000000278 spinal cord Anatomy 0.000 claims description 9
QMNUDYFKZYBWQX-UHFFFAOYSA-N 1H-quinazolin-4-one Chemical compound C1=CC=C2C(=O)N=CNC2=C1 QMNUDYFKZYBWQX-UHFFFAOYSA-N 0.000 claims description 8
208000024827 Alzheimer disease Diseases 0.000 claims description 8
206010046543 Urinary incontinence Diseases 0.000 claims description 8
239000003795 chemical substances by application Substances 0.000 claims description 8
229910052760 oxygen Inorganic materials 0.000 claims description 8
208000030507 AIDS Diseases 0.000 claims description 7
208000018737 Parkinson disease Diseases 0.000 claims description 7
206010043118 Tardive Dyskinesia Diseases 0.000 claims description 7
125000004429 atom Chemical group 0.000 claims description 7
125000000623 heterocyclic group Chemical group 0.000 claims description 7
229910052717 sulfur Inorganic materials 0.000 claims description 7
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 6
241000124008 Mammalia Species 0.000 claims description 6
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
239000001301 oxygen Substances 0.000 claims description 6
125000001544 thienyl group Chemical group 0.000 claims description 6
125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 5
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 5
239000011593 sulfur Substances 0.000 claims description 5
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 4
230000003042 antagnostic effect Effects 0.000 claims description 4
125000001246 bromo group Chemical group Br* 0.000 claims description 4
201000010099 disease Diseases 0.000 claims description 4
125000004432 carbon atom Chemical group C* 0.000 claims description 3
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 3
125000001424 substituent group Chemical group 0.000 claims description 3
JVQIKJMSUIMUDI-UHFFFAOYSA-N 3-pyrroline Chemical compound C1NCC=C1 JVQIKJMSUIMUDI-UHFFFAOYSA-N 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
125000005842 heteroatom Chemical group 0.000 claims description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
125000004076 pyridyl group Chemical group 0.000 claims description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 4
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 2
206010021639 Incontinence Diseases 0.000 claims 2
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
206010019233 Headaches Diseases 0.000 claims 1
231100000869 headache Toxicity 0.000 claims 1
125000002346 iodo group Chemical group I* 0.000 claims 1
206010027599 migraine Diseases 0.000 claims 1
230000000626 neurodegenerative effect Effects 0.000 abstract description 4
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 45
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 34
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
238000006243 chemical reaction Methods 0.000 description 30
239000002585 base Substances 0.000 description 26
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
239000002253 acid Substances 0.000 description 18
239000000243 solution Substances 0.000 description 18
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 16
239000002904 solvent Substances 0.000 description 16
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 16
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
229960000583 acetic acid Drugs 0.000 description 12
241000699670 Mus sp. Species 0.000 description 11
206010003497 Asphyxia Diseases 0.000 description 10
235000011054 acetic acid Nutrition 0.000 description 10
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
238000004458 analytical method Methods 0.000 description 9
239000011575 calcium Substances 0.000 description 9
239000007787 solid Substances 0.000 description 9
238000012360 testing method Methods 0.000 description 9
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
239000003981 vehicle Substances 0.000 description 8
239000011592 zinc chloride Substances 0.000 description 8
235000005074 zinc chloride Nutrition 0.000 description 8
206010012335 Dependence Diseases 0.000 description 7
125000004356 hydroxy functional group Chemical group O* 0.000 description 7
239000012442 inert solvent Substances 0.000 description 7
229940098747 AMPA receptor antagonist Drugs 0.000 description 6
239000000775 AMPA receptor antagonist Substances 0.000 description 6
208000000884 Airway Obstruction Diseases 0.000 description 6
206010008589 Choking Diseases 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
206010013647 Drowning Diseases 0.000 description 6
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 6
206010057852 Nicotine dependence Diseases 0.000 description 6
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 6
208000021063 Respiratory fume inhalation disease Diseases 0.000 description 6
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
208000025569 Tobacco Use disease Diseases 0.000 description 6
239000012267 brine Substances 0.000 description 6
239000003054 catalyst Substances 0.000 description 6
150000001768 cations Chemical class 0.000 description 6
239000003153 chemical reaction reagent Substances 0.000 description 6
206010013663 drug dependence Diseases 0.000 description 6
206010015037 epilepsy Diseases 0.000 description 6
230000007823 neuropathy Effects 0.000 description 6
201000001119 neuropathy Diseases 0.000 description 6
231100000252 nontoxic Toxicity 0.000 description 6
230000003000 nontoxic effect Effects 0.000 description 6
208000033808 peripheral neuropathy Diseases 0.000 description 6
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 5
241000700159 Rattus Species 0.000 description 5
208000009205 Tinnitus Diseases 0.000 description 5
150000007513 acids Chemical class 0.000 description 5
230000004913 activation Effects 0.000 description 5
150000001412 amines Chemical class 0.000 description 5
230000001684 chronic effect Effects 0.000 description 5
230000000694 effects Effects 0.000 description 5
239000002609 medium Substances 0.000 description 5
PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 5
102000005962 receptors Human genes 0.000 description 5
108020003175 receptors Proteins 0.000 description 5
230000002207 retinal effect Effects 0.000 description 5
231100000886 tinnitus Toxicity 0.000 description 5
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 4
206010014405 Electrocution Diseases 0.000 description 4
102000018899 Glutamate Receptors Human genes 0.000 description 4
108010027915 Glutamate Receptors Proteins 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
229910019142 PO4 Inorganic materials 0.000 description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
208000005298 acute pain Diseases 0.000 description 4
210000004556 brain Anatomy 0.000 description 4
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 4
235000019441 ethanol Nutrition 0.000 description 4
230000002461 excitatory amino acid Effects 0.000 description 4
239000003257 excitatory amino acid Substances 0.000 description 4
BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
239000010452 phosphate Substances 0.000 description 4
239000000047 product Substances 0.000 description 4
239000011541 reaction mixture Substances 0.000 description 4
229910052708 sodium Inorganic materials 0.000 description 4
229910052938 sodium sulfate Inorganic materials 0.000 description 4
235000011152 sodium sulphate Nutrition 0.000 description 4
208000011117 substance-related disease Diseases 0.000 description 4
230000005062 synaptic transmission Effects 0.000 description 4
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 3
125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
208000007848 Alcoholism Diseases 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
229910002651 NO3 Inorganic materials 0.000 description 3
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 3
239000012346 acetyl chloride Substances 0.000 description 3
239000003377 acid catalyst Substances 0.000 description 3
201000007930 alcohol dependence Diseases 0.000 description 3
JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
230000008878 coupling Effects 0.000 description 3
238000010168 coupling process Methods 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
239000013078 crystal Substances 0.000 description 3
239000012024 dehydrating agents‎ Substances 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
230000003492 excitotoxic effect Effects 0.000 description 3
231100000063 excitotoxicity Toxicity 0.000 description 3
238000001914 filtration Methods 0.000 description 3
239000012458 free base Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
229910052740 iodine Inorganic materials 0.000 description 3
239000007788 liquid Substances 0.000 description 3
238000002844 melting Methods 0.000 description 3
230000008018 melting Effects 0.000 description 3
230000004770 neurodegeneration Effects 0.000 description 3
210000002569 neuron Anatomy 0.000 description 3
239000004090 neuroprotective agent Substances 0.000 description 3
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
229910052700 potassium Inorganic materials 0.000 description 3
239000000843 powder Substances 0.000 description 3
230000008569 process Effects 0.000 description 3
238000010926 purge Methods 0.000 description 3
238000011160 research Methods 0.000 description 3
239000011734 sodium Substances 0.000 description 3
239000001632 sodium acetate Substances 0.000 description 3
235000017281 sodium acetate Nutrition 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 2
KWVPFECTOKLOBL-KTKRTIGZSA-N 2-[(z)-octadec-9-enoxy]ethanol Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCO KWVPFECTOKLOBL-KTKRTIGZSA-N 0.000 description 2
125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 2
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 description 2
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
208000022497 Cocaine-Related disease Diseases 0.000 description 2
DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 2
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
IRJCBFDCFXCWGO-UHFFFAOYSA-N Ibotenic acid Chemical compound OC(=O)C(N)C1=CC(=O)NO1 IRJCBFDCFXCWGO-UHFFFAOYSA-N 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
208000007101 Muscle Cramp Diseases 0.000 description 2
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
208000026251 Opioid-Related disease Diseases 0.000 description 2
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
229920005372 Plexiglas® Polymers 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 2
229940024606 amino acid Drugs 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
150000001413 amino acids Chemical group 0.000 description 2
150000008064 anhydrides Chemical class 0.000 description 2
150000001450 anions Chemical class 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
230000003197 catalytic effect Effects 0.000 description 2
229960003920 cocaine Drugs 0.000 description 2
201000006145 cocaine dependence Diseases 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
229910052805 deuterium Inorganic materials 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000000284 extract Substances 0.000 description 2
235000013305 food Nutrition 0.000 description 2
238000009472 formulation Methods 0.000 description 2
125000002541 furyl group Chemical group 0.000 description 2
239000012362 glacial acetic acid Substances 0.000 description 2
229940050410 gluconate Drugs 0.000 description 2
239000008103 glucose Substances 0.000 description 2
229930195712 glutamate Natural products 0.000 description 2
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 2
229950006874 kainic acid Drugs 0.000 description 2
239000008101 lactose Substances 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
239000006199 nebulizer Substances 0.000 description 2
230000000926 neurological effect Effects 0.000 description 2
125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 2
201000005040 opiate dependence Diseases 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
239000011591 potassium Substances 0.000 description 2
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
239000003586 protic polar solvent Substances 0.000 description 2
XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
238000012216 screening Methods 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
239000007921 spray Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000000725 suspension Substances 0.000 description 2
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
238000005303 weighing Methods 0.000 description 2
239000008096 xylene Substances 0.000 description 2
YFYNOWXBIBKGHB-MHTLYPKNSA-N (1r,3s)-1-aminocyclopentane-1,3-dicarboxylic acid Chemical compound OC(=O)[C@@]1(N)CC[C@H](C(O)=O)C1 YFYNOWXBIBKGHB-MHTLYPKNSA-N 0.000 description 1
SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 description 1
125000004505 1,2,4-oxadiazol-5-yl group Chemical group O1N=CN=C1* 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
125000004509 1,3,4-oxadiazol-2-yl group Chemical group O1C(=NN=C1)* 0.000 description 1
ZQXCQTAELHSNAT-UHFFFAOYSA-N 1-chloro-3-nitro-5-(trifluoromethyl)benzene Chemical compound [O-][N+](=O)C1=CC(Cl)=CC(C(F)(F)F)=C1 ZQXCQTAELHSNAT-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
UQNAFPHGVPVTAL-UHFFFAOYSA-N 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline Chemical compound N1C(=O)C(=O)NC2=C1C=C([N+]([O-])=O)C1=C2C=CC=C1S(=O)(=O)N UQNAFPHGVPVTAL-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
CSHJCESYHRWFCE-UHFFFAOYSA-N 2-amino-3-hydroxy-2-(5-methyl-1,2-oxazol-4-yl)propanoic acid Chemical compound CC=1ON=CC=1C(N)(CO)C(O)=O CSHJCESYHRWFCE-UHFFFAOYSA-N 0.000 description 1
AKCRQHGQIJBRMN-UHFFFAOYSA-N 2-chloroaniline Chemical compound NC1=CC=CC=C1Cl AKCRQHGQIJBRMN-UHFFFAOYSA-N 0.000 description 1
125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
AGNIOTWTCBTBJB-UHFFFAOYSA-N 3-(2-bromophenyl)-6-fluoro-2-(2-pyridin-2-ylethenyl)quinazolin-4-one Chemical compound C=1C=CC=C(Br)C=1N1C(=O)C2=CC(F)=CC=C2N=C1C=CC1=CC=CC=N1 AGNIOTWTCBTBJB-UHFFFAOYSA-N 0.000 description 1
FNKJVNLHOWAVES-UHFFFAOYSA-N 3-(2-chlorophenyl)-2-[2-(4,6-dimethylpyrimidin-2-yl)ethenyl]-6-fluoroquinazolin-4-one Chemical compound CC1=CC(C)=NC(C=CC=2N(C(=O)C3=CC(F)=CC=C3N=2)C=2C(=CC=CC=2)Cl)=N1 FNKJVNLHOWAVES-UHFFFAOYSA-N 0.000 description 1
DQVKTNIBBFXHLI-UHFFFAOYSA-N 3-(2-chlorophenyl)-2-[2-[6-[[2-(dimethylamino)ethyl-methylamino]methyl]pyridin-2-yl]ethenyl]-6-fluoroquinazolin-4-one Chemical compound CN(C)CCN(C)CC1=CC=CC(C=CC=2N(C(=O)C3=CC(F)=CC=C3N=2)C=2C(=CC=CC=2)Cl)=N1 DQVKTNIBBFXHLI-UHFFFAOYSA-N 0.000 description 1
ZFVWXCOZQAODAN-UHFFFAOYSA-N 3-(2-chlorophenyl)-6-fluoro-2-(2-pyridin-2-ylethenyl)quinazolin-4-one Chemical compound C=1C=CC=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1C=CC1=CC=CC=N1 ZFVWXCOZQAODAN-UHFFFAOYSA-N 0.000 description 1
APIPJJJAFWUWED-UHFFFAOYSA-N 3-(2-chlorophenyl)-6-fluoro-2-[2-(2-methyl-1,3-thiazol-4-yl)ethenyl]quinazolin-4-one Chemical compound S1C(C)=NC(C=CC=2N(C(=O)C3=CC(F)=CC=C3N=2)C=2C(=CC=CC=2)Cl)=C1 APIPJJJAFWUWED-UHFFFAOYSA-N 0.000 description 1
DXDZCWHOJFCJNI-UHFFFAOYSA-N 3-(2-chlorophenyl)-6-fluoro-2-[2-[6-[(2-methylpiperidin-1-yl)methyl]pyridin-2-yl]ethenyl]quinazolin-4-one Chemical compound CC1CCCCN1CC1=CC=CC(C=CC=2N(C(=O)C3=CC(F)=CC=C3N=2)C=2C(=CC=CC=2)Cl)=N1 DXDZCWHOJFCJNI-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical class OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
LVILGAOSPDLNRM-UHFFFAOYSA-N 4-methylpyrimidine Chemical compound CC1=CC=NC=N1 LVILGAOSPDLNRM-UHFFFAOYSA-N 0.000 description 1
GHYZIXDKAPMFCS-UHFFFAOYSA-N 5-fluoro-2-nitrobenzoic acid Chemical compound OC(=O)C1=CC(F)=CC=C1[N+]([O-])=O GHYZIXDKAPMFCS-UHFFFAOYSA-N 0.000 description 1
ZOZIPIYDVKHXNF-UHFFFAOYSA-N 6-bromo-3-(2-methylphenyl)-2-[2-(6-methylpyridin-2-yl)ethenyl]quinazolin-4-one Chemical compound CC1=CC=CC(C=CC=2N(C(=O)C3=CC(Br)=CC=C3N=2)C=2C(=CC=CC=2)C)=N1 ZOZIPIYDVKHXNF-UHFFFAOYSA-N 0.000 description 1
WCSMZAHKVXOYLH-UHFFFAOYSA-N 6-fluoro-1h-quinazolin-4-one Chemical compound N1C=NC(=O)C2=CC(F)=CC=C21 WCSMZAHKVXOYLH-UHFFFAOYSA-N 0.000 description 1
HVIXBXRHTSCRRM-UHFFFAOYSA-N 6-fluoro-2-methyl-3-(2-methylphenyl)quinazolin-4-one Chemical compound CC1=CC=CC=C1N1C(=O)C2=CC(F)=CC=C2N=C1C HVIXBXRHTSCRRM-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
201000006474 Brain Ischemia Diseases 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
108091005462 Cation channels Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
206010008748 Chorea Diseases 0.000 description 1
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
101100391174 Dictyostelium discoideum forC gene Proteins 0.000 description 1
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
241000792859 Enema Species 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
241000282412 Homo Species 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
238000000585 Mann–Whitney U test Methods 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
SGXDXUYKISDCAZ-UHFFFAOYSA-N N,N-diethylglycine Chemical compound CCN(CC)CC(O)=O SGXDXUYKISDCAZ-UHFFFAOYSA-N 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
102000004108 Neurotransmitter Receptors Human genes 0.000 description 1
108090000590 Neurotransmitter Receptors Proteins 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
101100391171 Schizosaccharomyces pombe (strain 972 / ATCC 24843) for3 gene Proteins 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229910000831 Steel Inorganic materials 0.000 description 1
229910052776 Thorium Inorganic materials 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
239000003929 acidic solution Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
239000003513 alkali Substances 0.000 description 1
150000001356 alkyl thiols Chemical class 0.000 description 1
239000000010 aprotic solvent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
238000003556 assay Methods 0.000 description 1
125000005604 azodicarboxylate group Chemical group 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
ZFXVRMSLJDYJCH-UHFFFAOYSA-N calcium magnesium Chemical compound [Mg].[Ca] ZFXVRMSLJDYJCH-UHFFFAOYSA-N 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
229960004424 carbon dioxide Drugs 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
230000032823 cell division Effects 0.000 description 1
208000037887 cell injury Diseases 0.000 description 1
230000006727 cell loss Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
229940116592 central nervous system diagnostic radiopharmaceuticals Drugs 0.000 description 1
210000000782 cerebellar granule cell Anatomy 0.000 description 1
208000012601 choreatic disease Diseases 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
230000019771 cognition Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
230000002999 depolarising effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
VLNZUSMTOFYNPS-UHFFFAOYSA-N diethylphosphorylformonitrile Chemical compound CCP(=O)(CC)C#N VLNZUSMTOFYNPS-UHFFFAOYSA-N 0.000 description 1
SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
230000002964 excitative effect Effects 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000012467 final product Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
239000007789 gas Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
239000008187 granular material Substances 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
230000001057 ionotropic effect Effects 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000006166 lysate Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229960003194 meglumine Drugs 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000004973 motor coordination Effects 0.000 description 1
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
230000003705 neurological process Effects 0.000 description 1
230000004007 neuromodulation Effects 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
230000036963 noncompetitive effect Effects 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
230000001242 postsynaptic effect Effects 0.000 description 1
235000011056 potassium acetate Nutrition 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
229940093956 potassium carbonate Drugs 0.000 description 1
235000011181 potassium carbonates Nutrition 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 1
238000000746 purification Methods 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
PMWXGSWIOOVHEQ-UHFFFAOYSA-N pyridine-2,6-dicarbaldehyde Chemical compound O=CC1=CC=CC(C=O)=N1 PMWXGSWIOOVHEQ-UHFFFAOYSA-N 0.000 description 1
125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
239000000376 reactant Substances 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
QBERHIJABFXGRZ-UHFFFAOYSA-M rhodium;triphenylphosphane;chloride Chemical compound [Cl-].[Rh].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QBERHIJABFXGRZ-UHFFFAOYSA-M 0.000 description 1
230000021317 sensory perception Effects 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
229940032147 starch Drugs 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000010959 steel Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000000946 synaptic effect Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 description 1
HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
229910052722 tritium Inorganic materials 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
229910052721 tungsten Inorganic materials 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
239000011995 wilkinson's catalyst Substances 0.000 description 1
UTODFRQBVUVYOB-UHFFFAOYSA-P wilkinson's catalyst Chemical compound [Cl-].C1=CC=CC=C1P(C=1C=CC=CC=1)(C=1C=CC=CC=1)[Rh+](P(C=1C=CC=CC=1)(C=1C=CC=CC=1)C=1C=CC=CC=1)P(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 UTODFRQBVUVYOB-UHFFFAOYSA-P 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Psychology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Compositions Of Macromolecular Compounds (AREA)
Paints Or Removers (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

OA9800216A 1996-05-15 1998-11-06 Novel 2,3 disubstituted-4(3H)-quinazolinones OA10918A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US1773896P	1996-05-15	1996-05-15

Publications (1)

Publication Number	Publication Date
OA10918A true OA10918A (en)	2001-10-25

Family

ID=21784266

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA9800216A OA10918A (en)	1996-05-15	1998-11-06	Novel 2,3 disubstituted-4(3H)-quinazolinones

Country Status (38)

Country	Link
US (1)	US6303615B1 (es)
EP (1)	EP0901487B9 (es)
JP (1)	JP3241388B2 (es)
KR (1)	KR100375155B1 (es)
CN (2)	CN1103772C (es)
AP (1)	AP1148A (es)
AR (1)	AR007118A1 (es)
AT (1)	ATE242232T1 (es)
AU (1)	AU730503B2 (es)
BG (1)	BG102999A (es)
BR (1)	BR9709085A (es)
CA (1)	CA2252907C (es)
CZ (1)	CZ295565B6 (es)
DE (1)	DE69722613T2 (es)
DK (1)	DK0901487T3 (es)
DZ (1)	DZ2237A1 (es)
EA (1)	EA002905B1 (es)
ES (1)	ES2198546T3 (es)
GT (1)	GT199700049A (es)
HN (1)	HN1997000052A (es)
HR (1)	HRP970261B1 (es)
HU (1)	HUP9902148A3 (es)
ID (1)	ID17149A (es)
IL (1)	IL126589A (es)
IS (1)	IS4881A (es)
MA (1)	MA26430A1 (es)
NO (1)	NO985293L (es)
OA (1)	OA10918A (es)
PL (1)	PL330042A1 (es)
PT (1)	PT901487E (es)
SI (1)	SI0901487T1 (es)
SK (1)	SK284108B6 (es)
TN (1)	TNSN97087A1 (es)
TR (1)	TR199802296T2 (es)
TW (1)	TW539675B (es)
WO (1)	WO1997043276A1 (es)
YU (1)	YU19197A (es)
ZA (1)	ZA974156B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1998038187A1 (en) *	1997-02-28	1998-09-03	Pfizer Products Inc.	Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditions
US6306864B1 (en) *	1997-02-28	2001-10-23	Pfizer Inc.	Atropisomers of 3-aryl-4(3H)-quinazolinones and their use as AMPA-receptor antagonists
US6060479A (en) *	1997-06-09	2000-05-09	Pfizer Inc	Quinazoline-4-one AMPA antagonists
IL125950A0 (en) *	1997-09-05	1999-04-11	Pfizer Prod Inc	Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
EP0900567A3 (en) *	1997-09-05	2001-05-02	Pfizer Products Inc.	Quinazoline-4-one AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy
JPH11279158A (ja) *	1998-02-09	1999-10-12	Pfizer Prod Inc	キナゾリン―４―オン誘導体の製造方法
CA2362385C (en) *	1999-02-15	2009-08-11	Eisai Co., Ltd.	Heterodiazinon compound
US6890930B1 (en) *	1999-09-28	2005-05-10	3-Dimensional Pharmaceuticals, Inc.	Quinazolinones
US7230000B1 (en)	1999-10-27	2007-06-12	Cytokinetics, Incorporated	Methods and compositions utilizing quinazolinones
US6545004B1 (en)	1999-10-27	2003-04-08	Cytokinetics, Inc.	Methods and compositions utilizing quinazolinones
US20020061897A1 (en)	2000-03-30	2002-05-23	Elliott Richard L.	Neuropeptide Y antagonists
US6667300B2 (en)	2000-04-25	2003-12-23	Icos Corporation	Inhibitors of human phosphatidylinositol 3-kinase delta
CN1245386C (zh)	2000-06-12	2006-03-15	卫材株式会社	1,2－二氢吡啶化合物及其制备方法和用途
AU2002366103A1 (en) *	2001-11-19	2003-06-10	Iconix Pharmaceuticals, Inc.	Modulators of rho c activity
GB0129260D0 (en)	2001-12-06	2002-01-23	Eisai London Res Lab Ltd	Pharmaceutical compositions and their uses
AU2003213092A1 (en)	2002-02-15	2003-09-09	Smithkline Beecham Corporation	Syntheses of quinazolinones
WO2003094839A2 (en)	2002-05-09	2003-11-20	Cytokinetics, Inc.	Pyrimidinone compounds, compositions and methods
US7214800B2 (en)	2002-05-09	2007-05-08	Cytokinetics, Inc.	Compounds, compositions, and methods
AU2003265242A1 (en)	2002-05-23	2003-12-22	Cytokinetics, Inc.	Compounds, compositions, and methods
WO2003106426A1 (en)	2002-06-14	2003-12-24	Cytokinetics, Inc.	Compounds, compositions, and methods
WO2004009036A2 (en) *	2002-07-23	2004-01-29	Cytokinetics, Inc.	Compounds compositions and methods
US7557115B2 (en)	2002-09-30	2009-07-07	Cytokinetics, Inc.	Compounds, compositions, and methods
US7439254B2 (en)	2003-12-08	2008-10-21	Cytokinetics, Inc.	Compounds, compositions, and methods
ES2605792T3 (es)	2004-05-13	2017-03-16	Icos Corporation	Quinazolinona usada como inhibidor de la fosfatidilinositol 3-quinasa delta humana
MY148809A (en)	2004-07-06	2013-05-31	Eisai R&D Man Co Ltd	Crystals of 1,2-dihydropyridine compound and their production process
JP2009514954A (ja)	2005-11-04	2009-04-09	ハイドラバイオサイエンシズインコーポレイテッド	Ｔｒｐｖ３機能を変調するための化合物
MX2009003673A (es)	2006-10-04	2009-04-22	Pfizer Prod Inc	Derivados de piridido[4,3-d]pirimidin-4(3h)-ona como antagonistas de los receptores de calcio.
WO2008140750A1 (en) *	2007-05-10	2008-11-20	Hydra Biosciences Inc.	Compounds for modulating trpv3 function
KR101593242B1 (ko) *	2007-09-26	2016-02-11	셀진 코포레이션	６-, ７- 또는 ８-치환된 퀴나졸리논 유도체, 및 그를 포함하는 조성물 및 그의 사용 방법
BRPI0906996B1 (pt)	2008-01-30	2021-06-22	Shin Poong Pharmaceutical Co., Ltd	Composto de quinazolino-2, 4-diona, processo para preparar um composto, e, composição farmacêutica
CN102271683B (zh)	2008-11-13	2014-07-09	吉里德卡利斯托加公司	恶性血液病的治疗
US9492449B2 (en)	2008-11-13	2016-11-15	Gilead Calistoga Llc	Therapies for hematologic malignancies
SG174529A1 (en)	2009-03-24	2011-10-28	Gilead Calistoga Llc	Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
KR20120005523A (ko)	2009-04-20	2012-01-16	길리아드 칼리스토가 엘엘씨	고형 종양의 치료 방법
MX2012000817A (es)	2009-07-21	2012-05-08	Gilead Calistoga Llc	Tratamiento para desordenes del higado con inhibidores pi3k.
WO2013105985A1 (en) *	2011-02-28	2013-07-18	Philadelphia Health & Education Corporation	Small molecule inhibitors of rad51 recombinase and methods thereof
CA2864305C (en)	2012-03-05	2021-02-16	Gilead Calistoga Llc	Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
JP2017500319A (ja)	2013-12-20	2017-01-05	ギリアードカリストガエルエルシー	（ｓ）−２−（１−（９ｈ−プリン−６−イルアミノ）プロピル）−５−フルオロ−３−フェニルキナゾリン−４（３ｈ）−オンの塩酸塩の多形形態
ES2752552T3 (es)	2013-12-20	2020-04-06	Gilead Calistoga Llc	Métodos de proceso para inhibidores de fosfatidilinositol 3-quinasa
NZ726360A (en)	2014-06-13	2018-04-27	Gilead Sciences Inc	Phosphatidylinositol 3-kinase inhibitors
CA3122705A1 (en)	2018-12-14	2020-06-18	Eisai R&D Management Co., Ltd.	Aqueous based pharmaceutical formulations of 1,2-dihydropyridine compounds
WO2021154966A1 (en)	2020-01-29	2021-08-05	Kamari Pharma Ltd.	Compounds and compositions for use in treating skin disorders
CN113831335A (zh) *	2020-06-24	2021-12-24	北京大学	吡啶[2,3-d]并嘧啶-4-(3H)-酮类化合物及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1195321B (de) *	1962-03-16	1965-06-24	Troponwerke Dinklage & Co	Verfahren zur Herstellung von substituierten Chinazolon-(4)-derivaten
DE1670416A1 (de) *	1966-12-30	1971-02-11	Chem Fab Von Heyden Gmbh Muenc	Verfahren zur Herstellung von aminosubstituierten Chinazolinonderivaten
GB1298603A (en)	1970-04-06	1972-12-06	Karamchand Premchand Private	Quinazolinone derivatives
AU543928B2 (en) *	1981-01-16	1985-05-09	Masayuki Ishikawa	4(311)-quinazolinone derivatives
GB9022785D0 (en)	1990-10-19	1990-12-05	Merck Sharp & Dohme	Therapeutic agents
WO1992013535A1 (en) *	1991-02-06	1992-08-20	Research Corporation Technologies, Inc.	Anticonvulsant substituted quinazolones
US5284957A (en)	1992-09-03	1994-02-08	Eli Lilly And Company	Excitatory amino acid receptor antagonists
DE69401583T2 (de)	1993-05-06	1997-06-12	Novonordisk As	[1,2,4-TRIAZOLO[4,3-a]CHINOXALINVERBINDUNGEN DEREN HERSTELLUNG UND VERWENDUNG
GB9400680D0 (en) *	1994-01-14	1994-03-09	Sandoz Ltd	Improvements in or relating to organic compounds
US6306864B1 (en)	1997-02-28	2001-10-23	Pfizer Inc.	Atropisomers of 3-aryl-4(3H)-quinazolinones and their use as AMPA-receptor antagonists

1997
- 1997-02-17 PT PT97901749T patent/PT901487E/pt unknown
- 1997-02-17 US US09/180,732 patent/US6303615B1/en not_active Expired - Fee Related
- 1997-02-17 HU HU9902148A patent/HUP9902148A3/hu unknown
- 1997-02-17 DE DE69722613T patent/DE69722613T2/de not_active Expired - Fee Related
- 1997-02-17 EP EP97901749A patent/EP0901487B9/en not_active Expired - Lifetime
- 1997-02-17 KR KR10-1998-0709205A patent/KR100375155B1/ko not_active Expired - Fee Related
- 1997-02-17 TR TR1998/02296T patent/TR199802296T2/xx unknown
- 1997-02-17 AU AU15549/97A patent/AU730503B2/en not_active Ceased
- 1997-02-17 CA CA002252907A patent/CA2252907C/en not_active Expired - Fee Related
- 1997-02-17 CZ CZ19983526A patent/CZ295565B6/cs not_active IP Right Cessation
- 1997-02-17 DK DK97901749T patent/DK0901487T3/da active
- 1997-02-17 WO PCT/IB1997/000134 patent/WO1997043276A1/en not_active Ceased
- 1997-02-17 AT AT97901749T patent/ATE242232T1/de not_active IP Right Cessation
- 1997-02-17 JP JP54068297A patent/JP3241388B2/ja not_active Expired - Fee Related
- 1997-02-17 ES ES97901749T patent/ES2198546T3/es not_active Expired - Lifetime
- 1997-02-17 CN CN97194654A patent/CN1103772C/zh not_active Expired - Fee Related
- 1997-02-17 SI SI9730555T patent/SI0901487T1/xx unknown
- 1997-02-17 EA EA199800923A patent/EA002905B1/ru not_active IP Right Cessation
- 1997-02-17 SK SK1520-98A patent/SK284108B6/sk unknown
- 1997-02-17 BR BR9709085A patent/BR9709085A/pt not_active Application Discontinuation
- 1997-02-17 PL PL97330042A patent/PL330042A1/xx unknown
- 1997-04-08 TW TW086104460A patent/TW539675B/zh active
- 1997-04-21 HN HN1997000052A patent/HN1997000052A/es unknown
- 1997-04-29 GT GT199700049A patent/GT199700049A/es unknown
- 1997-05-13 AR ARP970102001A patent/AR007118A1/es not_active Application Discontinuation
- 1997-05-14 DZ DZ970085A patent/DZ2237A1/fr active
- 1997-05-14 MA MA24613A patent/MA26430A1/fr unknown
- 1997-05-14 TN TNTNSN97087A patent/TNSN97087A1/fr unknown
- 1997-05-14 YU YU19197A patent/YU19197A/sh unknown
- 1997-05-14 ID IDP971603A patent/ID17149A/id unknown
- 1997-05-14 ZA ZA974156A patent/ZA974156B/xx unknown
- 1997-05-15 HR HR970261A patent/HRP970261B1/xx not_active IP Right Cessation
- 1997-05-15 AP APAP/P/1997/001003A patent/AP1148A/en active
- 1997-12-17 IL IL12658997A patent/IL126589A/xx not_active IP Right Cessation
1998
- 1998-10-27 IS IS4881A patent/IS4881A/is unknown
- 1998-11-06 OA OA9800216A patent/OA10918A/en unknown
- 1998-11-13 NO NO985293A patent/NO985293L/no unknown
- 1998-12-08 BG BG102999A patent/BG102999A/xx unknown
2002
- 2002-09-05 CN CN02131946A patent/CN1420114A/zh active Pending

Also Published As

Publication number	Publication date
DE69722613T2 (de)	2004-05-13
HRP970261B1 (en)	2003-06-30
EP0901487A1 (en)	1999-03-17
HUP9902148A2 (hu)	2000-04-28
NO985293L (no)	1999-01-13
NO985293D0 (no)	1998-11-13
SK152098A3 (en)	2000-05-16
IL126589A0 (en)	1999-08-17
CN1218464A (zh)	1999-06-02
HN1997000052A (es)	1997-06-26
ES2198546T3 (es)	2004-02-01
EA002905B1 (ru)	2002-10-31
ZA974156B (en)	1998-11-16
TNSN97087A1 (fr)	2005-03-15
MA26430A1 (fr)	2004-12-20
TR199802296T2 (xx)	1999-02-22
CZ295565B6 (cs)	2005-08-17
SI0901487T1 (en)	2003-10-31
GT199700049A (es)	1998-10-21
KR20000011054A (ko)	2000-02-25
AU1554997A (en)	1997-12-05
HK1019607A1 (en)	2000-02-18
JP3241388B2 (ja)	2001-12-25
CN1420114A (zh)	2003-05-28
AR007118A1 (es)	1999-10-13
AP1148A (en)	2003-02-28
JPH11514663A (ja)	1999-12-14
KR100375155B1 (ko)	2003-08-19
TW539675B (en)	2003-07-01
IL126589A (en)	2003-06-24
YU19197A (sh)	1999-09-27
IS4881A (is)	1998-10-27
EA199800923A1 (ru)	1999-06-24
EP0901487B9 (en)	2004-09-29
EP0901487B1 (en)	2003-06-04
HUP9902148A3 (en)	2002-11-28
AU730503B2 (en)	2001-03-08
CA2252907C (en)	2005-05-17
DZ2237A1 (fr)	2002-12-03
PL330042A1 (en)	1999-04-26
DE69722613D1 (de)	2003-07-10
PT901487E (pt)	2003-08-29
ATE242232T1 (de)	2003-06-15
AP9701003A0 (en)	1997-07-31
BR9709085A (pt)	1999-08-03
DK0901487T3 (da)	2003-08-25
CZ352698A3 (cs)	1999-11-17
ID17149A (id)	1997-12-04
HRP970261A2 (en)	2000-12-31
BG102999A (bg)	1999-09-30
US6303615B1 (en)	2001-10-16
CN1103772C (zh)	2003-03-26
CA2252907A1 (en)	1997-11-20
WO1997043276A1 (en)	1997-11-20
SK284108B6 (sk)	2004-09-08

Publication	Publication Date	Title
CA2252907C (en)	2005-05-17	Novel 2,3 disubstituted-4(3h)-quinazolinones
US6306864B1 (en)	2001-10-23	Atropisomers of 3-aryl-4(3H)-quinazolinones and their use as AMPA-receptor antagonists
EP0807633B1 (en)	2002-11-06	Novel 2,3-disubstituted-(5,6)- heteroarylfused-pyrimidine-4-ones
US6060479A (en)	2000-05-09	Quinazoline-4-one AMPA antagonists
EP0900799B1 (en)	2005-06-08	Novel atropisomers of 2,3-disubstituted-(5,6)-heteroarylfused-pyrimidin-4-ones
US6380204B1 (en)	2002-04-30	Atropisomers of 3-heteroaryl-4(3H)-quinazolinones for the treatment of neurodegenerative and CNS-trauma related conditions
CZ9902994A3 (cs)	2000-11-15	Aťropoisomery 3-aryl-4(3H)-chinazolinonů a jejich použití jako antagonizujících činidel receptoru AMPA
CZ9902995A3 (cs)	2000-12-13	Atropoisomery 3-heteroaryl-4(3H)-chinazolinonů I pro léčení neurodegenaritivních stavů a stavů odvozených od CNS-traumatu
MXPA99008012A (es)	2000-01-01	Atropisomeros de 3-aril-4(3h)-quinazolinonas